Literature DB >> 9385374

Characterisation of two different nonsense mutations, C6792A and C6792G, causing skipping of exon 37 in the NF1 gene.

L Messiaen1, T Callens, A De Paepe, M Craen, G Mortier.   

Abstract

Neurofibromatosis type 1 (NF1), characterised by peripheral neurofibromas, café-au-lait spots and iris Lisch nodules, is one of the most common inherited disorders. We have analysed exons 35 to 49 in 21 unrelated NF1 patients using reverse transcription-polymerase chain reaction and protein truncation analysis. In two unrelated patients we found skipping of exon 37 at the cDNA level. Sequence analysis of genomic DNA revealed the presence of a C6792A transversion in one patient and a C6792G transversion in a second patient; both transversions change the codon for tyrosine to a nonsense codon. Sequencing of the exonic sequences as well as the branch sites, and the 3' and 5' splice sites of exons 36, 37 and 38 did not reveal any additional sequence abnormality. This is the first report showing that nonsense mutations in the NF1 gene can induce the skipping of a constitutive exon.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9385374     DOI: 10.1007/s004390050590

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  12 in total

1.  Molecular diagnosis of neurofibromatosis type 1: 2 years experience.

Authors:  Siân Griffiths; Peter Thompson; Ian Frayling; Meena Upadhyaya
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

Review 2.  Splicing in action: assessing disease causing sequence changes.

Authors:  D Baralle; M Baralle
Journal:  J Med Genet       Date:  2005-10       Impact factor: 6.318

3.  Aberrant RNA splicing is the major pathogenic effect in a knock-in mouse model of the dominantly inherited c.1430A>G human RPE65 mutation.

Authors:  Yan Li; Rachel Furhang; Amanda Ray; Todd Duncan; Joseph Soucy; Rashid Mahdi; Vijender Chaitankar; Linn Gieser; Eugenia Poliakov; Haohua Qian; Pinghu Liu; Lijin Dong; Igor B Rogozin; T Michael Redmond
Journal:  Hum Mutat       Date:  2019-01-25       Impact factor: 4.878

4.  Nearby stop codons in exons of the neurofibromatosis type 1 gene are disparate splice effectors.

Authors:  S Hoffmeyer; P Nürnberg; H Ritter; R Fahsold; W Leistner; D Kaufmann; W Krone
Journal:  Am J Hum Genet       Date:  1998-02       Impact factor: 11.025

5.  A spectrum of ABCC6 mutations is responsible for pseudoxanthoma elasticum.

Authors:  O Le Saux; K Beck; C Sachsinger; C Silvestri; C Treiber; H H Göring; E W Johnson; A De Paepe; F M Pope; I Pasquali-Ronchetti; L Bercovitch; A S Marais; D L Viljoen; S F Terry; C D Boyd
Journal:  Am J Hum Genet       Date:  2001-08-31       Impact factor: 11.025

6.  Functional analysis of splicing mutations in exon 7 of NF1 gene.

Authors:  Irene Bottillo; Alessandro De Luca; Annalisa Schirinzi; Valentina Guida; Isabella Torrente; Stefano Calvieri; Cristina Gervasini; Lidia Larizza; Antonio Pizzuti; Bruno Dallapiccola
Journal:  BMC Med Genet       Date:  2007-02-12       Impact factor: 2.103

7.  Neurofibromatosis type 1 (NF1): a protein truncation assay yielding identification of mutations in 73% of patients.

Authors:  V M Park; E K Pivnick
Journal:  J Med Genet       Date:  1998-10       Impact factor: 6.318

8.  Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain.

Authors:  R Fahsold; S Hoffmeyer; C Mischung; C Gille; C Ehlers; N Kücükceylan; M Abdel-Nour; A Gewies; H Peters; D Kaufmann; A Buske; S Tinschert; P Nürnberg
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

9.  NF1 exon 7 skipping and sequence alterations in exonic splice enhancers (ESEs) in a neurofibromatosis 1 patient.

Authors:  Patrizia Colapietro; Cristina Gervasini; Federica Natacci; Livia Rossi; Paola Riva; Lidia Larizza
Journal:  Hum Genet       Date:  2003-09-06       Impact factor: 4.132

10.  The spectrum of NF1 mutations in Korean patients with neurofibromatosis type 1.

Authors:  Seon-Yong Jeong; Sang-Jin Park; Hyon J Kim
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.